Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | KIF11 | P52732 | 8/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA4 | P22748 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.38 |
| ▸ | TLR2 | O60603 | 1/20 | 0.37 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4130049 | 0.85 | KIF11 (0.39) | SMN1; SMN2KIF11HPGDALDH1A1KMT2A | |
| SCHEMBL16715243 | 0.84 | SMN1; SMN2 (0.39) | SMN1; SMN2KIF11HPGDALDH1A1KMT2A | |
| SCHEMBL18704722 | 0.82 | KIF11 (0.45) | SMN1; SMN2KIF11LMNA | |
| SCHEMBL2806972 | 0.81 | L3MBTL1 (0.43) | KIF11HPGDLMNA | |
| SCHEMBL4804833 | 0.79 | KIF11 (0.50) | KIF11 | |
| SCHEMBL4530986 | 0.79 | KIF11 (0.50) | KIF11 | |
| SCHEMBL23299724 | 0.79 | KIF11 (0.47) | KIF11HPGDLMNA | |
| SCHEMBL18704720 | 0.79 | KIF11 (0.56) | KIF11 | |
| SCHEMBL4531442 | 0.78 | KIF11 (0.52) | KIF11 | |
| SCHEMBL18670041 | 0.78 | TAAR1 (0.39) | SMN1; SMN2KIF11HPGDALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10472420-B2 | Immune response modifier conjugates | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2019-11-12 | — | — | US | disclosed |
| EP-3085373-A1 | IMMUNE RESPONSE MODIFIER CONJUGATES | 3M Innovative Properties Company (US) | 2016-10-26 | — | — | EP | disclosed |
| US-20150141625-A1 | IMMUNE RESPONSE MODIFIER CONJUGATES | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2015-05-21 | — | — | US | disclosed |
| US-8951528-B2 | Immune response modifier conjugates | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2015-02-10 | — | — | US | disclosed |
| US-20090035323-A1 | IMMUNE RESPONSE MODIFIER CONJUGATES | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2009-02-05 | — | — | US | disclosed |
| EP-1988896-A2 | IMMUNE RESPONSE MODIFIER CONJUGATES | 3M Innovative Properties Company (US) | 2008-11-12 | — | — | EP | disclosed |
| WO-2007100634-A2 | IMMUNE RESPONSE MODIFIER CONJUGATES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141625-A1 | IMMUNE RESPONSE MODIFIER CONJUGATES | IFNG, CD74, MYD88 | SMN1; SMN2 4620/4885KIF11 2020/4885HPGD 1584/4885 |
| US-20090035323-A1 | IMMUNE RESPONSE MODIFIER CONJUGATES | IFNG, CD74, MYD88 | SMN1; SMN2 4620/4885KIF11 2020/4885HPGD 1584/4885 |
| US-10472420-B2 | Immune response modifier conjugates | IFNG, CD74, MYD88 | SMN1; SMN2 4620/4885KIF11 2020/4885HPGD 1584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.